As discussed previously, denosumab is an emerging therapy that may help reduce FD lesion pain and reduce lesion growth, while burosumab is being investigated for its potential role in improving pain related to FGF23-mediated hypophosphatemia and osteomalacia. Here, FGF23 is linked to Fabry disease.